News
Popular searches: Influenza, Childhood cancer, Endometriosis, Inflammation
-
Cell therapies trial planned for COVID-19
More than 200,000 people have died from COVID-19 since January 2020. While Australia has been relatively spared from the onslaught of infections and deaths, our nation’s scientists need to be part of the global effort to address this pandemic.… Read more
-
Using our immune system to fight COVID-19
There is something unusual about the initial—or innate—immune response to COVID-19 compared to usual influenza patterns. … Read more
-
Inflammation and infectious diseases
Severe COVID-19 infection presents as excessive lung inflammation, involving the build-up of cells and fluid in the lungs. This phenomenon, known as ARDS, restricts breathing and causes damage to the lungs. Severely affected patients will need ventilator assistance in intensive care.… Read more
-
Hyper-acute inflammation in COVID-19
Sepsis is a hyper-acute inflammatory response leading to life-threatening organ dysfunction. Sepsis is usually caused by bacterial infections; however, the COVID-19 pandemic illustrates that hyper-acute inflammation can also be part of viral infections.… Read more
-
Male reproductive health problems could begin in the womb
Disruptions to male babies’ development early during pregnancy could have a profound effect on a man’s future reproductive health, according to new research.… Read more
-
Two bros, no lab, but a laptop and a microphone
Ben Amberg and Mikee Inocencio are, in their own words, “two bros who met while doing PhDs”.
When COVID-19 hit, the friends found themselves, like many of us, in a whole new world in lockdown without their daily banter.… Read more -
Weighing up home birth vs hospital in the wake of coronavirus
There’s been a reported surge in women seeking home births since the outbreak of coronavirus in Australia.
Research led by Hudson Institute has shown home birth is safe for women with low-risk pregnancies.… Read more -
US FDA approval sought for clinical trial – potential COVID-19 treatment
Biotech company Noxopharm is seeking approval from the US FDA for a clinical trial in COVID-19 patients of an end-stage prostate cancer drug, following a discovery by Hudson Institute researchers that it could act as an anti-inflammatory.… Read more
-
Our response to COVID-19
Hudson Institute has responded to the coronavirus outbreak (COVID-19) both scientifically and to protect the wellbeing of our staff and community. Our world-leading scientists are applying their expertise in hyper-inflammation, to find ways to reduce the body’s overwhelming inflammatory response and acute respiratory distress that is leading to loss of lives from COVID-19. During this… Read more
-
Cancer drug investigated as anti-inflammatory for lethal conditions including COVID-19
An existing cancer drug could potentially modify a severe hyper-inflammatory ‘storm’ associated with some conditions, which may include the COVID-19 virus, according to Hudson Institute researchers.… Read more